As part of the settlement, McKesson must add two independent directors to its board, increase compliance training for directors and improve its system to flag suspicious orders.
McKesson also agreed to separate the role of CEO and board chairman to increase governance protections.
The settlement included no admission of wrongdoing, though the judge said the investors had raised legitimate questions of whether the directors ignored red flags about opioid shipments, according to Bloomberg.
McKesson still faces thousands of other lawsuits related to the opioid crisis.
Read the full article here.
More articles on pharmacy:
BCBS, Civica Rx create subsidiary to cut generic drug costs
PhRMA spent a record $29M on lobbying in 2019
Former Insys CEO gets 30 months in prison
